HUTCHMED (China) Limited

HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company headquartered in Hong Kong, focused on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. Established over two decades ago as one of China's first global-focused novel drug discovery firms, it operates a fully integrated platform spanning research, development, manufacturing, and commercialization, with a dedicated team exceeding 1,800 personnel. The company has advanced more than ten in-house drug candidates into clinical studies worldwide, targeting key pathways such as MET, VEGFR, FGFR, CSF-1R, PI3Kδ, Syk, IDH, ERK, EGFR, BTK, and CD47. Notable approved oncology drugs include fruquintinib (ELUNATE® in China, FRUZAQLA® globally via Takeda), savolitinib (ORPATHYS® in China via AstraZeneca), and surufatinib (SULANDA® in China for neuroendocrine tumors), with ongoing global partnerships and investigational pipelines addressing solid tumors, hematological malignancies, and autoimmune conditions. HUTCHMED plays a pivotal role in bridging Eastern innovation with international markets, enhancing treatment options through selective, potent therapies designed to minimize toxicities.